Fig. 3: Progression-Free and overall survival in all patients and in correlation with TP53, RB1 and CCNE1 alterations. | Nature Communications

Fig. 3: Progression-Free and overall survival in all patients and in correlation with TP53, RB1 and CCNE1 alterations.

From: Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial

Fig. 3

A Progression-Free and Overall Survival in all patients. B Progression-Free Survival in patients with NSMP tumors with and without RB1/CCNE1 alterations. C Progression-Free Survival in patients with TP53 mutated tumors and NSMP tumors with and without RB1/CCNE1 alterations.

Back to article page